1[1]Murray PR,Baron EJ,Tenover FC,et al. Manual of Clinical Microbiology[M]. 7th ed.Amercian Society for Microbiology, 1999,1488-1490.
2Hiramatsu K, Aritaka N, Hanaki H, et al Dissemination in Japanese hospital of strains of Staphylococcus aureus heterogeneously resistant to vancomycin [J]. The Lancet,1997 ; 350(12): 1670
3Hanaki H, Inaba Y, Sasaki K, et al. A novel method of detecting Staphylococcus aureus heterogeneously resistant to vancomycin [J]. Jpn J Antibiot, 1998; 521 (21): 51
4Shopsin B, Mathema B, Martinez J, et al. Prevalence of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in the community [J]. J Infect Dis,2000;182:359
6Markowitz N, Quinn E L, Saravolatz L D. Trimethoprim sulfamethoxazole compared with vancomycin for treatment of Staphylococcus aureus infection [J]. Ann Intern Med,1992;117:390
7Tamer M A, Bray J D. Trimethoprim sulfamethoxazole treatment of mulit-ant ibiotic-resistan t staphylococcal endocarditis and meningitis [J]. Clin Pediatr, 1986; 21:125
8Smith S M, Mangia A, Eng R H, et al. Clindamycin for eolonization and infection by methicillin-resistant Staphylococcus aureus [J]. Infection, 1988; 16: 95
9Maeski S, Mashimoto H, Araki J, et al. A case of MRSA sepsis treated by sequential combination therapy with netilmicin and minocycline [J].Kansenshogaku Zasshi, 1994; 68:1523
10Qadri S M, Ueno Y, Abu Mostafa F M, et al.In vitro activity of quinupristin/dalfopristin RP59500, against gram-positive clinical isolates[J]. Chemotherapy, 1997; 43 : 94
9BHATt'ACHARYA S, MONDAL A S. Clinical microbiology in the intensive care unit: strategic and operational characteristics [ J ]. Indian J Med Microbiol,2010,28( 1 ) :5 - 10.
10National Committee for Clinical Laboratory Standards. Performance standards for antinficmbial susceptibility testing [ S ]. NCCI..S, 2008 : 1 - 50.
